Showing results (1-10 of 212) with videos related to
Sort By:
Pageof 22
Seminars in Hematology|July 8, 2025
The genomic landscape of acute myeloid leukemia: Redefining classifications, ontogeny, and therapeutic strategiesNicolas Duployez, Claude PreudhommeBritish Journal of Haematology|June 27, 2024
Monitoring molecular changes in the management of myelodysplastic syndromesNicolas Duployez, Claude PreudhommeSeminars in Hematology|June 5, 2003
Mutations in the ABL kinase domain pre-exist the onset of imatinib treatmentCatherine Roche-Lestienne, Claude PreudhommeCurrent Opinion in Hematology|May 27, 2009
Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?Hervé Dombret, Claude Preudhomme, Nicolas BoisselExpert Review of Hematology|November 8, 2016
Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologistsNicolas Duployez, Sophie Lejeune, Aline Renneville, et al.Medecine Sciences : M/S|December 8, 2004
[Origin of resistance to Imatinib mesylate: lessons learned from this experience]Catherine Roche-Lestienne, François-Xavier Mahon, Claude PreudhommeCancer|October 28, 2014
Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rulesJoëlle Guilhot, Claude Preudhomme, Francois Xavier Mahon, et al.Seminars in Hematology|June 23, 2017
Familial CEBPA-mutated acute myeloid leukemiaKiran Tawana, Ana Rio-Machin, Claude Preudhomme, et al.Expert Review of Hematology|October 29, 2014
Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factorsNicolas Duployez, Christophe Willekens, Alice Marceau-Renaut, et al.Haematologica|June 14, 2005
Mutations of PTPN11 are rare in adult myeloid malignanciesLeroy Hugues, Hélène Cavé, Nathalie Philippe, et al.Pageof 22